The debate reveals a genuinely balanced risk/reward. The bull makes a compelling valuation case (19x forward for a 7.5% revenue compounder at a cyclical inflection with 3.15% yield and beta of 0.40), and the technical structure remains bullish. However, the bear exposes critical weaknesses that prevent a Buy: (1) volume is declining on the rally — a textbook exhaustion pattern, not accumulation; (2) the bull's $74-78 target requires multiple expansion to 22-24x while simultaneously arguing "multiple expansion fuel is gone" — an internal contradiction that undermines the entire thesis; (3) capital returns of $4.87B exceeded operating cash flow of $4.51B in FY25, with net debt up $2.7B in a single year — capital returns are partially debt-funded at 5%+ rates; (4) forward EPS of $3.36 is consensus and vulnerable to revision if cocoa spikes again or Q3/Q4 disappoint; (5) FY25's 1,070 bps gross margin compression may be partially structural, not purely cyclical; (6) the stock has already moved 21% YTD — much of the easy recovery money has been made. The bear's structural concerns (GLP-1 drugs, health trends) are real but longer-duration than a 12-month horizon. The path to $74 requires multiple positive surprises to align; the path to $55 requires multiple negative surprises. Neither is the base case. Hold reflects the genuine balance of evidence — neither aggressive accumulation nor trimming is warranted at current levels.

POSITION SIZING: Maintain current exposure. Do not add aggressively at $63.61 — the risk/reward is balanced, not compelling.

ADD LEVELS: Modest add (25% of planned increment) on pullback to 50 SMA at ~$61.04 ONLY if accompanied by volume capitulation spike (>10M shares) suggesting a washout. Full add zone: $58-60 (near 200 SMA at $57.90), representing ~7-9% pullback and improving risk/reward materially. Do NOT add on slow drift lower — that's distribution, not accumulation.

TRIM/TRIGGER LEVELS: Trim 25% of position on confirmed break below 50 SMA ($61.04) on expanding volume — signals bullish stack breaking. Trim 50% on break below 200 SMA ($57.90) — long-term trend violated. Exit entirely on break below $55 — recovery thesis invalidated.

CATALYSTS TO MONITOR: Q3 2026 earnings: focus on gross margin trajectory vs. 28.4% FY25 print. Move toward 31%+ confirms recovery; stagnation at 28-29% breaks thesis. Cocoa futures (CC): move below $7,000/lb confirms normalization; spike above $12,000 would force consensus EPS revisions lower. Hershey (HSY) quarterly results: sector read-through on chocolate pricing power and volume trends. Fed/Polymarket rate cut probabilities: rise from 15% to 40%+ would re-open multiple expansion door.

HOLD INVALIDATION (to Overweight): Decisive break above $66.65 (July 29 high) on volume >15M shares with improving cocoa data would signal next leg up and warrant adding.

HOLD INVALIDATION (to Underweight): Break below $57.90 on volume, or Q3 miss with negative guidance revision, would warrant trimming.

The investment plan presents a genuinely balanced risk/reward profile for MDLZ. The bull case (19x forward P/E, 7.5% revenue compounder, 3.15% yield, defensive beta of 0.40) is offset by legitimate structural concerns: declining volume on the rally suggests exhaustion rather than accumulation; capital returns of $4.87B exceeded operating cash flow of $4.51B in FY25 with net debt up $2.7B (partially debt-funded at 5%+ rates); and the bull's $74-78 target requires multiple expansion to 22-24x while simultaneously arguing that expansion fuel is gone — an internal contradiction. With the stock already up 21% YTD and at $63.61, much of the easy recovery has been captured. The plan's defined action zones (add at $58-60 with volume capitulation, trim below 50 SMA at $61.04, exit below $55) provide clear frameworks for responding to technical breaks, but currently the price sits in a neutral zone between these levels. Holding preserves exposure to the Q3 2026 earnings catalyst and cocoa normalization thesis without forcing a directional bet.

Stop loss: $55.00

Sizing: Maintain current exposure; do not add at current levels. Resume accumulation only on confirmed weakness: 25% increment near 50 SMA ($61.04) with volume capitulation (>10M shares), full add zone at $58-60 near 200 SMA ($57.90). Avoid adding on slow drift lower (distribution, not accumulation).